Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron for Multisystem Functional Decline in Aging and Obesity
NCT06987383Phase 3
Key facts
- Status
- Recruiting
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Countries
- 1
- Sponsor
- Wake Forest University Health Sciences
- Modality
- Small Molecules
- Drugs
- vibegron
- Conditions
- obesity
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Vibegron with Placebo (2 arms). Primary endpoint: Resting Metabolic Rate at 12 weeks. Started Oct 2026; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Vibegron
Participants receive 75mg/day Vibegron for 12 weeks.
Placebo
Participants receive placebo daily for 12 weeks.
03
Who it enrols
Middle-aged and older adults (45-75 years) with obesity (BMI >=30 or >=27 with high waist circumference), without major depression, cognitive impairment, uncontrolled diabetes, or recent significant weight change.
04
Endpoints
Primary
Resting Metabolic Rate
Secondary
Glucose Tolerance Level
Expanded Short Physical Performance Battery
Beyond the preview
Go deeper on NCT06987383.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987383.